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Background: Aldosterone synthase (CYP11B2) deficiency is a rare autosomal recessive disorder, usually presenting
with severe salt-wasting in infancy or stress-induced hyperkalaemia and postural hypotension in adulthood.
Neonatal screening for congenital adrenal hyperplasia, another cause of salt wasting, using 17-hydroxyprogesterone
measurement would fail to detect aldosterone synthase deficiency, a diagnosis which may be missed until the
patient presents with salt-wasting crisis. Due to this potential life-threatening risk, comprehensive hormonal
investigation followed by genetic confirmation for suspected patients would facilitate clinical management of the
patient and assessment of the genetic implication in their offspring.
Case presentation: We describe a 33-year old Chinese man who presented in infancy with life-threatening
hyponatraemia and failure to thrive, but remained asymptomatic on fludrocortisone since. Chromosomal analysis
confirmed a normal male karyotype of 46, XY. Plasma steroid profile showed high plasma renin activity, low
aldosterone level, and elevated 18-hydroxycorticosterone, compatible with type 2 aldosterone synthase deficiency.
The patient was heterozygous for a novel CYP11B2 mutation: c.977C > A (p.Thr326Lys) in exon 3. He also carried a
heterozygous mutation c.523_525delAAG (p.Lys175del) in exon 6, a known pathogenic mutation causing aldosterone
synthase deficiency. Sequencing of CYP11B2 in his parents demonstrated that the mother was heterozygous for
c.977C > A, and the father was heterozygous for c.523_525delAAG.
Conclusion: Although a rare cause of hyperreninaemic hypoaldosteronism, aldosterone synthase deficiency should be
suspected and the diagnosis sought in patients who present with life-threatening salt-wasting in infancy, as it has a
good long-term prognosis when adequate fludrocortisone replacement is instituted. To our knowledge, this is the first
Chinese patient in which the molecular basis of aldosterone synthase deficiency has been identified.
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Aldosterone is the main mineralocorticoid hormone in
humans that regulates sodium excretion and intravascular
volume. It acts via distal renal tubules and cortical collect-
ing ducts by increasing sodium reabsorption from and po-
tassium excretion into the urine. It is synthesized by
aldosterone synthase (CYP11B2), an enzyme encoded by
CYP11B2, expression of which is almost entirely confined* Correspondence: cok436@ha.org.hk
2Department of Pathology, The University of Hong Kong, Queen Mary
Hospital, Pokfulam Road, Pokfulam, Hong Kong
Full list of author information is available at the end of the article
© 2014 Hui et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.to the adrenal cortex and exclusively in the zona glo-
merulosa layer. Aldosterone synthase is a cytochrome
P450 enzyme that catalyses the final 3 steps of aldoster-
one biosynthesis: first by the hydroxylation of deoxycor-
ticosterone (DOC) at position 11β to form corticosterone
(B), then the hydroxylation at position 18 to form 18-
hydroxycorticosterone (18OHB), and lastly the oxidation
at position 18 to aldosterone [1]. Isolated deficiencies of
aldosterone biosynthesis are caused by inactivating muta-
tions in the CYP11B2 gene [2,3]. Aldosterone deficiency
leads to excessive sodium excretion and potassium re-
tention, resulting in hyponatraemia, hyperkalaemia, and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Plasma steroid profile of the patient
Basal (nmol/L) Post-ACTH stimulation
(nmol/L)
Aldosterone 0.166 (0.39-2.44) 0.19 (0.01 – 0.55)
18-OH-Corticosterone
(18-OHB)
7.06 (0.56 – 1.46) 12.1 (0.83 – 5.5)
Corticosterone 44.4 (0.14 – 14.23) 151.8 (34.0 - 208.4)
18-OH-
deoxycorticosterone
1.64 (0.13-0.72) 5.28 (0.58 – 6.1)
Deoxycorticosterone 0.57 (0.09 – 0.57) 2.36 (0.27 – 1.35)
Progesterone 1.94 (0.095 – 3.15) 2.96 (0.52 – 2.55)
17-
hydroxyprogesterone
3.09 (0.24 – 4.93) 15.2 (1.88 – 10.96)
11-Deoxycortisol 2.22 (0.15-2.58) 14.5 (1.36 - 9.44)
Cortisol 274.3 (59.9 - 480) 721.5 (317.3 – 979.3)
Cortisone 161.2 (6.37-123.6) 59.9 (34.8 – 79.7)
Ratio
B/18-OHB 6 12
18-OHB/ aldo 43 63
Plasma steroid profile showed low aldosterone level, elevated
18-hydroxycorticosterone (18-OHB), low corticosterone/18-OHB and high
18-OHB/aldosterone ratios, compatible with type 2 aldosterone synthase deficiency.
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ficiency (ASD) have been identified in Iranian Jews,
Europeans and North Americans [4]. In Asians, it has
been reported in Thai, Japanese and Indian individuals
[5,6]. To our knowledge, there has been no report of
Chinese cases with confirmed genetic analysis. Here,
we describe a case of aldosterone synthase deficiency
in a Chinese man and results of CYP11B2 analysis in
the patient and his family.
Case presentation
Case report
The index patient, at the time of this report aged 33 years
old, was delivered normally at term with a birth weight of
3.1 kg. He had repeated vomiting with poor feeding and
failure to thrive at 5 weeks of age. He was found to have
hyponatraemia and was started on cortisone acetate 2.5 mg
three times daily and fludrocortisone 50 μg daily on the
presumptive diagnosis of congenital adrenal hyperplasia.
He had normal male phenotype and chromosomal ana-
lysis confirmed a normal male karyotype of 46, XY. He
was evaluated with supervised treatment withdrawal by
6 months old. 24-hour urinary ketosteroid was normal
but plasma renin activity was high and aldosterone was
low, suggestive of hypoaldosteronism. Cortisone acetate
was subsequently stopped. Plasma steroid profiling, which
was performed after withholding therapy for a week at the
age of 14.5 years old, gave characteristic findings of type 2
ASD (Table 1). Developmental milestones, electrolytes
and blood pressure were normal while on fludrocortisone
100 μg daily. Both his unrelated parents and his older
brother were phenotypically normal.
Genetic analysis
During family planning, genetic analysis was performed to
ascertain the diagnosis at the age of 33 years. Blood samples
were obtained and genomic DNA extracted from the pa-
tient, his brother and both non-consanguineous parents
with informed consent. The nine coding exons and flanking
intronic regions (15 bp) of the CYP11B2 gene were ampli-
fied by polymerase chain reaction on the patient’s genomic
DNA, followed by direct DNA sequencing using primers
and conditions as previously described [5]. Targeted muta-
tional analysis was also performed on both parents and his
brother’s genomic DNA. The patient and family members’
DNA sequences were compared to NCBI Reference Se-
quences, NG_008374.1, NM_000498.3 and NP_000489.3.
The affected patient carried a novel heterozygous mis-
sense mutation: c.977C > A (p.Thr326Lys) in exon 3
(Figure 1), which has not previously been reported. He
also carried a heterozygous mutation c.523_525delAAG
(p.Lys175del) in exon 6, a known pathogenic frameshift
mutation causing ASD [7]. Sequencing of CYP11B2 in the
parents demonstrated that the mother was heterozygousfor c.977C > A (p.Thr326Lys) and the father was heterozy-
gous for c.523_525delAAG (p.Lys175del). Neither muta-
tion was detected in the patient’s brother.Discussion
We describe a Chinese man who presented with severe
salt-wasting in infancy and hyperreninaemic hypoaldos-
teronism, and in whom genetic analysis confirmed aldos-
terone synthase deficiency. He remained clinically well
in adulthood with normal electrolytes and blood pres-
sure whilst on fludrocortisone.
Inadequate aldosterone production results in decreased
renal sodium reabsorption and potassium excretion in
ASD. Clinical severity varies, with the most severe forms
presenting in infancy. Affected infants usually develop
vomiting, dehydration, hypovolaemia, and failure to thrive
at a few days to weeks following delivery [8]. However, salt-
losing crisis in isolated ASD is usually indistinguishable
clinically from other forms of defective steroid biosyn-
thesis, such as 21-hydroxylase deficiency in congenital
adrenal hyperplasia. Therefore, life-threatening salt-
wasting in affected infants is usually treated initially
with both hydrocortisone and fludrocortisone pending
steroid hormone analysis [9]. Phenotypically, infants
with ASD have normal external genitalia [5]. Hydro-
cortisone can be withdrawn once characteristic steroid
profile or genetic mutations of CYP11B2 gene are con-
firmed. A typical biochemical profile of this disorder
includes hyponatraemia, hyperkalaemia, raised plasma
Figure 1 Electropherogram of segment of CYP11B2 showing the heterozygous c.977C > A mutation. The mutation site is denoted by the
letter N and is indicated by an arrow.
Hui et al. BMC Endocrine Disorders 2014, 14:29 Page 3 of 5
http://www.biomedcentral.com/1472-6823/14/29renin activity, undetectable or low aldosterone level,
and normal or elevated cortisol levels.
Aldosterone synthase deficiency has been classified based
on biochemical phenotypes: in type 1 ASD, the enzymatic
CYP11B2 activity is completely abolished. Affected indi-
viduals have low to normal levels of 18OHB, and un-
detectable to low levels of plasma aldosterone or its
urinary metabolite, tetrahydroaldosterone [10]. In type
2 deficiency, the mutations in the CYP11B2 gene only
decrease 18-hydroxylase and 18-oxidase activities, but
not 11β-hydroxylase activity. It differs from type 1 in
that 18-OHB levels are markedly elevated, whilst plasma
aldosterone levels and urinary tetrahydroaldosterone are
low [7]. However, it is now recognised that these biochem-
ical phenotypes have clinical, hormonal and genotypic
overlapping features [11] and that type 1 and type 2 ASD
would be better considered a continuous spectrum of the
same disease [5].
As clinical severity gradually improves with age, affected
adults are usually asymptomatic despite no mineralocortic-
oid therapy [5,12]. However, termination of mineralocortic-
oid may lead to postural hypotension and hyperkalaemia
when triggered by stress due to dehydration or reduced salt
intake in some affected adults [12]. Generalised weakness
with marked hyperkalaemia and dehydration has been re-
ported as the first presentation in a middle-aged man after
concurrent institution of indapamide for hypertension and
bowel preparation for barium enema. Interestingly, further
questioning revealed a past history of vomiting and failure
to thrive in early infancy that resolved without any min-
eralocorticoid replacement [13]. Therefore, detailed
childhood history would be a helpful clue in suspected
ASD case presenting in adulthood. Possible mechanisms
for reduced clinical severity of ASD with advancing age in-
clude increasing sensitivity to mineralocorticoid actionand sodium intake with age. It has been shown that min-
eralocorticoid receptor expression in human kidneys begins
with low levels in late gestation and rises progressively after
birth [14]. Another potential mechanism is age-dependent
impaired 11β-hydroxysteroid dehydrogenase type 2 activity,
leading to greater cortisol availability for the mineralocor-
ticoid receptor with age [15].
Neonatal screening for CAH using 17-hydroxyprogesterone
measurement would fail to detect ASD, as infants with
ASD usually have normal [12] or slightly elevated basal
and stimulated 17-hydroxyprogesterone [9]. The diagnosis
of ASD may therefore be missed until the patient presents
with salt-wasting crisis. Therefore, comprehensive hormo-
nal investigation followed by genetic confirmation for sus-
pected adults and their respective partners would be
useful to assess the genetic implication in their offspring
and to minimize the potential life-threatening risk.
Compound heterozygosity has been reported when
phenotypically unaffected parents contribute to each allele
with a heterozygous mutation, rendering phenotypes of
ASD type 1 in the affected offspring [6,10]. Our current
case inherited one of the heterozygous mutations
c.977C > A (p.Thr326Lys) maternally, and the other
c.523_525delAAG (p.Lys175del) paternally. The un-
affected parents are heterozygous for their respective
mutations, in accordance with an autosomal recessive
inheritance. In silico protein function prediction using
PolyPhen-2 and Align GVGD both predict the novel
missense variant c.977C > A (p.Thr326Lys) to be dam-
aging. Multiple sequence alignment of the CYP11B2
gene also showed that the threonine residue is highly
conserved across multiple mammal species (Table 2).
The threonine residue in codon 326 is located in the I-
helix of CYP11B2 protein (Figure 2). A previous study
mapping the amino acid difference between CYP11B2







Codon 326 of the CYP11B2 gene in homo sapiens and the corresponding
codon in other species are in bold phase. The threonine residue at codon 326
(in bold) is highly conserved across different mammal species.
Figure 2 3-D model of the CYP11B2 mutant with the novel
missense c.977C > A mutation. The threonine residue in codon
326 is located in the I-helix of CYP11B2 protein, which is implicated
in 18-hydroxylation/oxidation due to the clusters of CYP11B2
isoform-specific residues in that region. In particular, the alanine
residue in position 320 is required for methyloxidase reaction and the
p.Thr318Met in the I-helix is a known deleterious mutation causing
aldosterone synthase deficiency. This structural information and
functional correlation suggest that the I-helix region, where the novel
variant c.977C > A (p.Thr326Lys) is located, is important for the enzyme
activity of CYP11B2.
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residues are clustered around the H-helix and in the I-
helix and are essential for 18-hydroxylation/oxidation
[16]. In particular, the alanine residue in position 320
in CYP11B2 is required for methyloxidase reaction.
Also, p.Thr318Met in the I-helix is a known deleterious
mutation causing aldosterone synthase deficiency [11].
This structural information and functional correlation
suggest that the I-helix region, where the novel variant
c.977C > A (p.Thr326Lys) is located, is important for
enzyme activity of CYP11B2. Taking all the aforemen-
tioned factors into consideration, the variant c.977C >
A (p.Thr326Lys) is likely to be pathogenic, in keeping
with our case.
Homozygous p.Lys175del (previously described as homo-
zygous deletion of codon 173 before the use of the latest
HGVS nomenclature) has been reported in a girl presenting
with salt-wasting during infancy [7]. CYP11B2 is poly-
morphic at this position, encoding arginine or lysine.
Amino acid residue 173 is positioned in α-helix D, and
the secondary structure of aldosterone synthase was
presumed to be altered by the single amino acid dele-
tion. Indeed, using fission yeast system, Tin et al. dem-
onstrated that the deletion mutation at codon 173
displayed markedly reduced 11-β-hydroxylation activity
(16.3%), and no 18-hydroxylation and 18-oxidation ac-
tivities [17].
Conclusion
Aldosterone synthase deficiency is a rare cause of hyper-
reninaemic hypoaldosteronism and its genetic and mo-
lecular basis is more heterogeneous than previously
described. It should be suspected in infants without viril-
isation presenting with salt-wasting or in adults present-
ing with stress-induced hyperkalaemia and a history of
failure to thrive in childhood. Our case illustrates the
clinical significance to recognize this condition as it has
a good long-term prognosis when adequate fludrocorti-
sone replacement is instituted.
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